FDA Approves Depakote (Divalproex) Extended Release For Migraine Prevention
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Depakote (Divalproex) Extended Release For Migraine Prevention

NEW YORK, NY -- October 13, 2000 -- The FDA recently approved Depakote ER (divalproex sodium extended-release tablets), a once-a-day formulation for the prevention of migraine headaches in adults.

Developed by Abbott Laboratories, Depakote ER is currently available by prescription in the U.S.

An estimated 28 million Americans suffer from migraines. Migraines can be debilitating, and can disrupt daily activities and job performance. Statistics show migraine sufferers miss 157 million workdays every year at a cost of as much as 17 billion dollars to the U.S. economy.

By taking Depakote ER just once a day, frequent migraine sufferers can prevent migraines before they start, and enjoy their lives again.

Related links: Depakote and Abbott Laboratories.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities